Inovio Pharmaceuticals Statistics

Total Valuation

LON:0A43 has a market cap or net worth of GBP 81.07 million. The enterprise value is 51.18 million.

Market Cap	81.07M
Enterprise Value	51.18M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	68.70M
Shares Outstanding	n/a
Shares Change (YoY)	+53.38%
Shares Change (QoQ)	+34.35%
Owned by Insiders (%)	0.42%
Owned by Institutions (%)	50.25%
Float	68.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	597.65
PB Ratio	-14.12
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.64
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.77

Financial Position

The company has a current ratio of 0.79

Current Ratio	0.79
Quick Ratio	0.74
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.11
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -328.45% and return on invested capital (ROIC) is -127.02%.

Return on Equity (ROE)	-328.45%
Return on Assets (ROA)	-63.56%
Return on Invested Capital (ROIC)	-127.02%
Return on Capital Employed (ROCE)	20,471.69%
Weighted Average Cost of Capital (WACC)	12.08%
Revenue Per Employee	1,012
Profits Per Employee	-600,107
Employee Count	134
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.17% in the last 52 weeks. The beta is 1.63, so LON:0A43's price volatility has been higher than the market average.

Beta (5Y)	1.63
52-Week Price Change	-15.17%
50-Day Moving Average	1.83
200-Day Moving Average	1.98
Relative Strength Index (RSI)	44.48
Average Volume (20 Days)	14,510

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.43

Income Statement

In the last 12 months, LON:0A43 had revenue of GBP 135,648 and -80.41 million in losses. Loss per share was -2.07.

Revenue	135,648
Gross Profit	-42.14M
Operating Income	-66.74M
Pretax Income	-80.41M
Net Income	-80.41M
EBITDA	-65.63M
EBIT	-66.74M
Loss Per Share	-2.07

Full Income Statement

Balance Sheet

The company has 37.79 million in cash and 7.45 million in debt, with a net cash position of 30.34 million.

Cash & Cash Equivalents	37.79M
Total Debt	7.45M
Net Cash	30.34M
Net Cash Per Share	n/a
Equity (Book Value)	-5.74M
Book Value Per Share	-0.11
Working Capital	-10.89M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -66.15 million and capital expenditures -117,731, giving a free cash flow of -66.27 million.

Operating Cash Flow	-66.15M
Capital Expenditures	-117,731
Free Cash Flow	-66.27M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-49,202.81%
Pretax Margin	-59,281.60%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0A43 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-53.38%
Shareholder Yield	-53.38%
Earnings Yield	-99.19%
FCF Yield	-81.75%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 25, 2024. It was a reverse split with a ratio of 0.0833333333.

Last Split Date	Jan 25, 2024
Split Type	Reverse
Split Ratio	0.0833333333

Scores

LON:0A43 has an Altman Z-Score of -40.51 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-40.51
Piotroski F-Score	3